Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

NCT01099540 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT01099540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01099540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2010
Completion date
March 31, 2013
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumor